Merck said it closed an underwritten public offering of Floating Rate Notes due 2027, 3.850% Notes due 2027, 4.150% Notes due 2030, 4.550% Notes due 2032, 4.950% Notes due 2035 and 5.700% Notes due 2055, comprising 6 series of notes, on September 9, 2025.

1. 01

   Merck said it closed an underwritten public offering of Floating Rate Notes due 2027, 3.850% Notes due 2027, 4.150% Notes due 2030, 4.550% Notes due 2032, 4.950% Notes due 2035 and 5.700% Notes due 2055, comprising 6 series of notes, on September 9, 2025.

2. 02

   The company said the aggregate principal amount of Floating Rate Notes due 2027 was $500,000,000, 3.850% Notes due 2027 was $750,000,000, 4.150% Notes due 2030 was $750,000,000 and 4.550% Notes due 2032 was $1,000,000,000.

3. 03

   Merck said the aggregate principal amount of 4.950% Notes due 2035 was $1,750,000,000 and 5.700% Notes due 2055 was $1,250,000,000. It added that these two series had the longest maturities among the 6 series in this offering.

4. 04

   The company said the notes were issued under its Form S-3ASR registration statement (Registration No. 333-278066, as amended by Post-Effective Amendment No. 1 filed on May 14, 2024) originally filed on March 19, 2024, and were issued pursuant to an indenture dated January 6, 2010 between the company and U.S. Bank Trust National Association, as trustee.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.